# Rapport Therapeutics, Inc. (RAPP): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Rapport Therapeutics, Inc. (RAPP) is 12/100, ranked against 24,000+ stocks in 35 markets (Quality 27, Value 26, Momentum 34, each scored against its sector).

- StockRank: 12/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 27, Value 26, Momentum 34: each a 0-100 percentile within Healthcare.
- Position: #23,188 overall, #2,184 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 25.33 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 1.7M; directors sold USD 8.1M; 5%+ holders sold USD 6.1M.

Source: https://moatmap.ai/stock/RAPP
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker